New Weight-Loss shot brenipatide enters early human testing

NCT ID NCT07476118

First seen Mar 21, 2026 · Last updated Apr 28, 2026 · Updated 6 times

Summary

This early-stage study tests a new drug called brenipatide in healthy adults who are overweight or have obesity. The goal is to see how well different doses help with weight loss and whether they are safe. Participants will receive injections under the skin and be followed for about 42 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fortrea Clinical Research Unit

    RECRUITING

    Dallas, Texas, 75247, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit - Daytona Beach

    RECRUITING

    Daytona Beach, Florida, 32117-5116, United States

    Contact Phone: •••-•••-••••

    Contact

  • Fortrea Clinical Research Unit Inc. - Madison

    RECRUITING

    Madison, Wisconsin, 53704, United States

    Contact Phone: •••-•••-••••

    Contact

Conditions

Explore the condition pages connected to this study.